CliffBio
small molecule

NELARABINE

NELARABINE

Loss of exclusivity—loss of exclusivity
CompanyNexus Labs →See this company's full patent-cliff portfolio

Drug detail

Brand nameNELARABINE
Active ingredientNELARABINE
Strength250MG/50ML (5MG/ML)
Dosage formINJECTABLE
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJune 2023
Marketing statusRX

More from Nexus Labs

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

NELARABINE patent cliff — loss of exclusivity — | CliffBio